Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Borden Ladner Gervais LLP ordered by Published Date Descending.
Links to Result pages
1 2 3 4 5 6 7  
All Eyes On Hospitals: Mandatory Drug And Medical Device Adverse Event Reporting
Traditionally, Health Canada has only required drug and medical device manufacturers to report serious adverse drug reactions and adverse events involving these products
10 Jul 2019
Revised Canadian Intellectual Property Enforcement Guidelines: Worth A Closer Look
On March 13, 2019, the Canadian Competition Bureau issued revised Intellectual Property Enforcement Guidelines (the IPEGs).
8 Jul 2019
The Disposition Of Human Remains/Tissues — A Short Guide For Hospitals
We frequently get asked questions by hospital clients about who has authority after the death of a patient to authorize the release of a body to a funeral home, to decide on burial or cremation
8 Mar 2019
Ontario Superior Court Filters Out Proposed Medical Implant Device Class Action
It is often said that product liability cases are ideal for class treatment.
18 Dec 2018
Spotlight On Medical Implant Devices Spurs Regulatory Changes
In the past few days, there has been increased media attention in Canada and around the world on the safety, efficacy, and regulation of medical implant devices.
5 Dec 2018
Increased Media Coverage On Medical Devices
Over the weekend and continuing into today, there have been numerous reports in the press about alleged problems with medical devices in Canada, the U.S., the UK, and elsewhere.
29 Nov 2018
Life Signs — Life Sciences Legal Trends In Canada
This publication is the most recent effort on our part to share with our clients and friends insights into some of the issues that we address in our efforts to advise the sector.
10 Aug 2018
CIPO's Examination Guidelines For Medical Diagnostic Methods Turn Three
This article provides a retrospective on three years of experience with the examination guidelines established by the Canadian Intellectual Property Office ...
18 Jul 2018
BLG Releases Fifth Life Sciences Legal Trends Report
​Toronto (June 4, 2018) — Borden Ladner Gervais (BLG) releases the fifth annual edition of its report Life Sciences Legal Trends in Canada (LifeSigns). The report features key insights...
6 Jun 2018
Court Of Appeal Affirms Judgment Finding Patent Invalid Due To Insufficient Disclosure (Intellectual Property Weekly Abstracts - Week of July 31, 2017)
This is an appeal of the Federal Court's decision allowing Gilead's claim to invalidate Idenix's ‘191 Patent on the grounds of insufficient disclosure and lack of demonstrated utility/sound prediction.
3 Aug 2017
Life Sciences Legal Trends In Canada - 2017
A report on Intellectual Property, Litigation, Corporate Commercial legal trends and industry developments in Canada.
26 Jun 2017
Apotex's Claims Against Current And Former Ministers And Civil Servants Working At The Ministry Of Health Is Not Struck For A Lack Of Jurisdiction (Intellectual Property Weekly Abstracts Bulletin — Week of May 29, 2017)
The Federal Court has refused to strike a claim brought by Apotex against current and former ministers and civil servants working at the Ministry of Health.
1 Jun 2017
Apotex Granted Leave To Expand Scope Of Evidence Available To Prove Its NIA Plea (Intellectual Property Weekly Abstracts - Week Of April 10, 2017)
In this recently reported decision, the Court granted Apotex leave to deliver Fresh as Amended Responding Statement of Issues for the reference into AstraZeneca's damages or Apotex's profits, following the Court's decision that the ‘693 Patent is valid and infringed by Apotex.
13 Apr 2017
Unparticularized Allegations Made Pursuant to S. 53 Struck Without Leave to Amend (Intellectual Property Weekly Abstracts - Week of January 30, 2017)
In this case, Apotex started an action to impeach Shire's patent relating to lisdexamfetamine dimesylate. Shire brought a motion to strike portions of Apotex's Reply.
1 Feb 2017
Threatening Cease And Desist Letters Supporting Claim Under Section 7(A) Of The Trade-Marks Act In An Impeachment Action (Intellectual Property Weekly Abstracts Bulletin — Week of December 5)
This decision concerned the validity and/or infringement of a number of claims in three Canadian Patents. The Plaintiffs in the impeachment action were collectively referred to as the Excalibre Parties.
8 Dec 2016
An Unsuccessful Defendant Is Not Entitled To Elect An Accounting Of Profits To Shield Itself From An Award Of Damages (Intellectual Property Weekly Abstracts - Week of November 7, 2016)
On September 7, 2016, the Court held that Bayer's patent was valid and infringed (2016 FC 1013; our summary here). The parties were given an opportunity to make written submissions regarding Bayer's entitlement to elect between damages and an accounting of profits.
10 Nov 2016
NOA Found To Be Deficient For Failing To Plead The Facts And Law Relating To The Manufacture And Importation Of The Drug Product (Intellectual Property Weekly Abstracts Bulletin — Week of October 3)
Bayer has obtained an order of prohibition against the Minister of Health from issuing a NOC to Fresenius for its proposed moxifloxacin hydrochloride product.
6 Oct 2016
Links to Result pages
1 2 3 4 5 6 7